Skip to content

Fate Therapeutics Inc

FATE· NasdaqCore metricsCIK 1434316

Biological products, except diagnostic substances175 peers

Last sale
Nov 12, 2026 · -16.87%
Market cap
$161.69M
121.57M shares
Filings
858
$0.00
Q3 2026−51.2% FY25 yoy
-$30.69M
Q3 2026N/M FY25 yoy
-$32.25M
Q3 2026N/M FY25 yoy
-$82.47M
Q3 2026derivedN/M FY25 yoy
-$0.25
Q3 2026N/M FY25 yoy
$43.94M
Q3 2026+29.3% FY25 yoy
$161.69M
—
34.0×
1.2×
-66.16%
—

Twelve months to Sep 30, 2026 · derived

Price

$1.33+18.75%+$0.21past year
Nov 12, 2026 · IEX last sale
Figure
Range
IEX last saleClose of recordAs traded

Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Financials

Revenue

$6.65MFY 2025
$96.30M0FY 2013FY 2019FY 2025
PeriodEndedValueKindSource trail
FY 20252025-12-31$6,646,000reported
FY 20242024-12-31$13,631,000reported
FY 20232023-12-31$63,533,000reported
FY 20222022-12-31$96,300,000reported
FY 20212021-12-31$55,846,000reported
FY 20202020-12-31$31,434,000reported
FY 20192019-12-31$10,680,000reported
FY 20182018-12-31$4,740,000reported
FY 20172017-12-31$4,106,000reported
FY 20162016-12-31$4,402,000reported
FY 20152015-12-31$2,431,000reported
FY 20132013-12-31$971,000reported

Capital returns

Fiscal yearDividendsBuybacksTotalPer shareSharesShares · yoyof free cash flow
FY2011—$7.00K$7.00K————

Segments

Products
Revenue by Products, FY2022 to FY2023FY2022Commercial Option Exercise Member · FY2022 · $13.00MAssociated with collaboration services · FY2022 · $1.30MFY2023Commercial Option Exercise Member · FY2023 · $10.00M
LineFY2023ShareChange
Commercial Option Exercise Member$10.00M16%−23.1%
Associated with collaboration services———
Total$63.53M

From the 10-K filed Mar 5, 2025FATE

Biological products, except diagnostic substances

Fate Therapeutics Inc is the 65th largest of the 176 covered companies the SEC files under this code, by revenue. SIC 2836

Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.

Fate Therapeutics Inc · CIK 1434316 · Engraved from SEC EDGAR